Electrosurgical debulking of pretibial myxedema of the foot
| Autor: | Jacob Levitt, Erisa Alia, Eric J Feit |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
endocrine system
medicine.medical_specialty endocrine system diseases business.industry Graves' disease Pretibial myxedema medicine.medical_treatment Thyroid Octreotide Dermatology General Medicine Debulking medicine.disease Autoimmune thyroiditis 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure pretibial myxedema elephantiasic pretibial myxedema electrosurgical debulking electrosurgery Graves disease medicine Rituximab Plasmapheresis business medicine.drug |
| Zdroj: | Alia, Erisa; Feit, Eric J.; & Levitt, Jacob Oren. (2019). Electrosurgical debulking of pretibial myxedema of the foot. Dermatology Online Journal, 25(2). Retrieved from: http://www.escholarship.org/uc/item/4hb7q330 |
| ISSN: | 1087-2108 |
| DOI: | 10.5070/d3252042916 |
| Popis: | Pretibial myxedema or thyroid dermopathy constitutes dermal deposition of mucin, primarily hyaluronic acid and chondroitin sulfate. It is a manifestation of autoimmune thyroiditis, seen more in Graves disease than in Hashimoto thyroiditis. The time delay from treatment of hyperthyroidism to appearance of localized myxedema varies from one month to 16 years (mean 5.13 years). Despite a variety of therapeutic options, failure and relapse rates are high. Therapeutic options reported in the literature include compression, topical and intralesional corticosteroids, oral pentoxifylline, octreotide, rituximab, plasmapheresis, and high-dose intravenous immunoglobulin. We share our experience in two patients who were treated with electrosurgical debulking of selected longstanding myxedematous lesions, with one positive result and one negative result. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|